Ribbon Biolabs Raises Eur 18 Million Series A Financing Enabling Commercial Scale Production Facilities And Us Expansion For Dna Synthesis Technology

Ribbon Biolabs, the DNA synthesis company, today announced the successful close of EUR 18 million in its Series A funding round from a consortium of European and US investors led by Hadean Ventures and with participation from Lansdowne Partners, Helicase Venture as well as several undisclosed investors. Existing investors IST cube and tecnet equity also joined in the round.